FDA approves breakthrough drug daraxonrasib to deal with pancreatic cancer

The US Food and Drug Administration has authorized a remedy for pancreatic cancer that, in medical trials, practically doubled the general survival time for sufferers.

The drug, daraxonrasib, offered under the model title Rasonque and manufactured by Revolution Medicines, seems to be a breakthrough in treating one of the world’s deadliest cancers.

A late-stage medical trial with 500 sufferers discovered those who took the day by day tablet had an average survival time of 13.2 months, in contrast to 6.6 months for those on chemotherapy.

The FDA said the drug offered a “critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer”.

Daraxonrasib helps forestall the unfold of cancer by locking onto and shutting off the mutated KRAS gene, which is in more than 90% of pancreatic tumours and spurs cancer growth.

Each 12 months, roughly 67,000 people in the US are recognized with pancreatic cancer, which has the highest mortality charge of all main cancers, according to the American Cancer Society..

Pancreatic cancer is usually noticed late and is notoriously tough to deal with. More than half of those with pancreatic cancer die within three months of diagnosis.

In 2025, the FDA granted the drug a “Breakthrough Therapy” designation, given to therapies for critical situations that warrant an expedited review.

The company then authorized the drug six months forward of the regulatory deadline because it “showed unprecedented results in an area of high unmet need”, said Angelo de Claro, director of the the company’s Oncology Center of Excellence.

The most common unwanted side effects of the remedy were rash, diarrhoea, nausea, fatigue and vomiting, the FDA said. About 44% of sufferers on daraxonrasib skilled extreme unwanted side effects, in contrast to 57.5% handled with chemotherapy in the trial.

Former US Senator Ben Sasse, who announced in December he had been recognized with Stage 4 pancreatic cancer, is in a medical trial for the drug and has said it has helped shrink his tumours.